glp-1 for diabetic receptor agonists individualized treatment of type 2 diabetes mellitus GLP-1 receptor agonism: a transformative
Description
Why it matters: Microdoses of GLP-1s are not FDA approved, but the ad hoc practice of smaller doses began taking off on social media last year
Consequently, only a limited portion of the expenditures shown in Figure 2 is attributable to non-obesity-related indications
This can lead to daytime fatigue, headaches and other short-term symptoms, as well as an increased risk of cardiovascular disease, diabetes and mental health changes
In a retrospective study completed by Nadeem et al., it was shown that GLP-1 RAs are associated with an overall fourfold increase in the retention of gastric contents in both diabetic and non-diabetic patients ( p -value 0.8 mL/kg of gastric fluid content (measured from the aspiration/suction canister)
Optum Perks is owned by RVO Health
Bioelectrical Impedance Analysis (BIA)
